PTPRC and neoplasm: The treatment with P2Et, αPD-L1 or P2Et plus αPD-L1 significantly increased the number of CD45+ cells per mg of 4T1 tumor (Supplementary Figure 6A), with an increase in CD4+ and CD8+ T cells (Supplementary Figure 6B).